Study of BrudyGlauco DHA and Citicoline to Protect Vision in Adults with Glaucoma Randomized, Double-Blind, Placebo-Controlled Trial Lasting 12 Months

What this Trial Is About

Researchers are investigating the potential neuroprotective effects of BrudyGlauco, a nutritional supplement containing docosahexaenoic acid DHA and citicoline, in people with glaucoma. Glaucoma causes progressive damage to the optic nerve, leading to vision loss, and current treatments mainly focus on lowering eye pressure. This study aims to see if BrudyGlauco can protect or improve visual function beyond existing therapies. Participants will be randomly assigned to receive either BrudyGlauco or a placebo containing sunflower oil. They will take two capsules orally at lunchtime each day for 12 months. The trial is double-blind and placebo-controlled, involving regular eye exams and visual field tests to measure changes in vision during and after treatment. An interim analysis will be done at 6 months to assess safety and early effects. During the study, participants will undergo ophthalmologic evaluations including visual field testing and measurement of DHA levels in blood samples using the Dry Blood Spot method. Researchers will monitor changes in visual function, treatment adherence, and safety. Follow-up will continue for 3 months after treatment ends to observe any lasting effects. The total participation duration is about 15 months, including treatment and post-treatment monitoring.

Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma